ÀÖÓãµç¾º





û±ØÒªÄÇôÐß´ð´ð£¬½â¶ÁÒõµÀ·ÖÃÚÎï¼ìÑéµÄËùÓÐÒÉÎÊ£¡

·¢²¼ÈÕÆÚ£º2020-08-13

¹Ø°®Å®ÐÔ½¡¿µ£¬¹Ø×¢ÉúÖ³½¡¿µ¡£Å®ÐÔÉúÖ³½¡¿µ£¬²»½öÉæ¼°×ÔÉíµÄ½¡¿µÎÊÌ⣬¶øÇÒ¶ÔÆä¼ÒÍ¥µÄÐÒ¸£¼°Éç»áµÄºÍгÓëÎȶ¨¶¼ÓÐ×ÅÒ»¶¨µÄÓ°Ïì¡£½üÄêÀ´£¬Å®ÐÔÉúÖ³½¡¿µÎÊÌâÒ»Ö±±¶ÊܹØ×¢¡£Ñо¿±íÃ÷£¬È«Çò³¬¹ý20%µÄÅ®ÐÔ»¼Óи¾¿Æ¼²²¡[1]£¬¶øÎÒ¹ú¸¾²ú¿Æ¸ÐȾÐÔ¼²²¡·¢²¡ÂÊÔÚÅ®ÐÔÈËȺÖÐÔ¼Õ¼40%£¬¶ø¼¸ºõËùÓеĸ¾²ú¿Æ¸ÐȾ¶¼°éËæ×ÅÅ®ÐÔÉúÖ³µÀÄÚ»·¾³µÄ¸Ä±ä[2]¡£

²»Í¬ÄêÁä¶ÎµÄÅ®ÐÔ¾ùÓпÉÄܻỼÓÐÏàÓ¦µÄ¸¾¿Æ¼²²¡£¬ÑîÆ¼[3]¶ÔÁÙ´²Ëæ»ú³éÈ¡586ÀýÕë¶Ô²»Í¬ÄêÁä¶Î²¢»¼Óи¾¿Æ¼²²¡µÄ»¼Õß½øÐÐͳ¼Æ£¨¼û±í1£©£¬·¢ÏÖÄêÁäÔÚ31-45ËêÖ®¼äµÄ»¼Õß·¢²¡ÂÊ×î¸ß£¬ÓÐÐÔÉú»îÊ·Õß·¢²¡ÂʽÏÎÞÐÔÉú»îÊ·Õß·¢²¡Âʸߡ£

\

±í1.²»Í¬ÄêÁä¶Î»¼Õ߸¾¿Æ¼²²¡ÖÖÀà·Ö²¼Çé¿öͳ¼Æ[3]

×¢£º²»×ã30Ë껼ÕßÕ¼23.55%£¬31-45ËêÖ®¼ä»¼ÕßÕ¼66.21%£¬´óÓÚ46ËêÕ¼10.24%¡£

¸¾¿Æ¼²²¡¿ÉÄܵ¼Ö¸¾Å®É¥Ê§ÉúÓýÄÜÁ¦£¬ÑÏÖØÊ±»¹»áΣ¼°»¼ÕßÉúÃü¡£ÓÐÑо¿¶Ô4019Àý¸¾¿ÆÃÅÕﻼÕßµÄÒõµÀ΢»·¾³Çé¿ö½øÐзÖÎö£¬ÆäÖÐÃ÷È·¸ÐȾÕßÕ¼32.94%£¬¶ø24.33%ΪÍâÒõÒõµÀ¼ÙË¿½Íĸ²¡£¨Õæ¾úÐÔÒõµÀÑ×£©VVC£¬3.11%ΪÐèÑõ¾úÐÔÒõµÀÑ×£¨AV£©£¬3.14%Ϊϸ¾úÐÔÒõµÀ²¡£¨BV£©£¬5.15%ΪµÎ³æÐÔÒõµÀÑ×£¨TV£©£¬»ìºÏÐÔ¸ÐȾռ8.31%[4]¡£Óɴ˿ɼûAV¡¢BV¡¢VVC¡¢TVµÈΪÁÙ´²³£¼ûµÄÒõµÀÑ×£¬Ò²ÊǸ¾¿Æ¼²²¡·¢ÉúµÄ“µ¼»ðË÷”¡£¶ø°×´ø³£¹æ¼ì²âÊÇÅжÏÅ®ÐÔÃÚÄòÉúÖ³µÀ½¡¿µË®Æ½ÖÐÒ»ÏîÖØÒªµÄҽѧ¼ì²éÏîÄ¿¡£

\

±í2.³£¼ûÒõµÀÑ×µÄÒâÒå

Å®ÐÔÒõµÀÊÇÓÉÍêÕûµÄ¸´²ãÁÛ×´ÉÏÆ¤Ï¸°û¸²¸Ç£¬½¡¿µ³ÉÄêµÄÅ®ÐÔÒõµÀÉÏÆ¤Ï¸°û»áÊÍ·Å´óÁ¿µÄÌÇÔ­¡£ÆäÖÐǰͥ´óÏÙ¡¢ÄòµÀÅÔÏÙ¡¢×Ó¹¬¾±ÄÉʽÏÙ·ÖÃÚµÄÕ³Òº£¬×Ó¹¬ÄÚĤºÍÊäÂѹܵȲ¿Î»·ÖÃÚµÄÒºÌ壬ÒÔÉø³öÎïµÄÐÎʽ´ÓճĤϲãÅųö£¬³ÆÎª¸¾¿Æ·ÖÃÚÎ¼´“°×´ø”¡£

\

ͼ1.Å®ÐÔÉúÖ³Æ÷¹¹Ôìͼ

ÔçÔÚ1892Ä꣬DederleinÊ״η¢±íÁËÓйØÓÚÅ®ÐÔÒõµÀÄÚ»·¾³¾úȺµÄÑо¿£¬ËûÈÏΪŮÐÔÒõµÀ΢ÉúÎï½öÓɸïÀ¼ÑôÐԸ˾ú¹¹³É£¬¼´ÈéËá¸Ë¾ú£¬µ«ºóÆÚͨ¹ý´«Í³ÅàÑø·¨ÔÚÒõµÀ·ÖÃÚÎïÖзÖÀë³ö 50¶àÖÖ΢ÉúÎ¶ø½¡¿µÅ®ÐÔµÄÒõµÀ·ÖÃÚÎïÖУ¬ÈéËá¸Ë¾úµÄ·ÖÀëÂʸߴï50%~80%¡£ÏÖÒÑÈ·¶¨£¬¶¨ÖµÓÚÕý³£ÒõµÀÄÚµÄ΢ÉúÎïȺÖ÷ÒªÓÉϸ¾ú¡¢Õæ¾ú¡¢Ô­³æ¡¢Ö§Ô­Ìå¡¢ÒÂÔ­ÌåºÍ²¡¶¾×é³É£¬Ö÷ÒªÆÜÏ¢ÓÚÒõµÀËÄÖܵIJà±ÚճĤñÞÖåÖУ¬Æä´ÎÊÇñ·Â¡£¬²¿·ÖÔÚ¹¬¾±´¦[5]¡£

\

±í3.Å®ÐÔÒõµÀ΢»·¾³ÖоúȺ·ÖÀà

Õý³£¸¾Å®ÒõµÀÖеĶàÖÖ΢ÉúÎïÓëËÞÖ÷Ö®¼ä±£³Ö×Ŷ¯Ì¬Æ½ºâ£¬Î¢ÉúÎïÏ໥֮¼äÒ²±£³Ö×Ŷ¯Ì¬Æ½ºâ[6]¡£Ö®ËùÒÔÄÜά³ÖÒõµÀÄÚ»·¾³µÄÏà¶Ôƽºâ£¬ÊÇÒòΪËüÃÇÏà»¥ÖÆÔ¼¡¢Ï໥Эµ÷£¬¿É¿´×÷Õý³£ÉúÀí½á¹¹µÄÒ»²¿·Ö£¬ÊÇÒ»¸öϵͳ[7]¡£ÒõµÀÄÚµÄÈéËá¸Ë¾ú¿É²úÉúÈéËáºÍ¹ýÑõ»¯Ç⣬¿Éά³ÖÒõµÀÄÚµÄËáÐÔ»·¾³£¬·ÀÖ¹ÆäËûÍâÀ´²¡Ô­Î¢ÉúÎïÈëÇÖ£¬Ò»µ©Æ½ºâ¹ØÏµ±»´òÆÆ£¬½«»á³öÏÖÏàÓ¦µÄ¸¾¿Æ¼²²¡¡£ÒõµÀÇå½à¶È¼ì²é£¬¿É¸ù¾Ý¾µÏ°×ϸ°û¡¢ÉÏÆ¤Ï¸°û¡¢ÒõµÀ¸Ë¾ú¡¢ÔÓ¾úµÄ¶àÉÙÀ´ÅжÏÒõµÀÄÚ»·¾³µÄ×´¿ö¡£¼û±í4[8]¡£

\

±í4.Å®ÐÔÒõµÀÇå½à¶È·Ö¼¶±ê×¼[8]

ʵÑéÊÒ¼ì²â³õÆÚ²ÉÓÃÏÔ΢¾µ·¨½øÐа״øÊªÆ¬Í¿Æ¬¼ì²é£¬¹Û²ìÏÔ΢¾µÏµÄÓÐÐγɷ֣»Ëæ×ÅÈËÃÇÈÏ֪ˮƽºÍ¿ÆÑ§¼¼ÊõµÄ½ø²½£¬ÔÚÁÙ´²»¯Ñ§ÖУ¬Ðí¶àеÄÓÐÖØÒªÒâÒåµÄÏîÄ¿±»¼ÓÈë½øÀ´¡£

½¡¿µ¸¾Å®ÒõµÀÖÐÕý³£ÓÅÊÆ¾úȺΪÈéËá¸Ë¾ú£¬¿Éͨ¹ý²úÉú¹ýÑõ»¯Çâ¡¢ÈéËᡢϸ¾úËØ¶ø¶ÔÌõ¼þÖ²¡¾úÓÐÞ׿¹×÷Ó㬱£»¤»úÌåÃâÊÜÖ²¡¾úµÄÇÖÏ®¡£³ÂµÂÁéµÈÈ˽øÐÐ1935Àý»¼ÕßµÄÒõµÀ·ÖÃÚÎïʵÑ飬½«¹ýÑõ»¯ÇâŨ¶ÈÒÔ2μmol/LΪ½Úµã£¬·ÖÎö¹ýÑõ»¯ÇâŨ¶È¸Ä±äÓëÒõµÀ·ÖÃÚÎïÖ÷ÒªÖ¸±ê¼ì³öÂʹØÏµ£¬½á¹û±íÃ÷¹ýÑõ»¯ÇâŨ¶È¸ßÔò¿É¼õÉÙÆäËûÖ²¡¾úµÄ¼ì³öÂÊ£¬¹ýÑõ»¯ÇâŨ¶È¿É×÷ΪÒõµÀÄÚ»·¾³×´¿öÃô¸ÐÖ¸±ê[9]¡£ÈéËáÓë¹ýÑõ»¯Ç⹲ͬ¼à²â£¬ÔòΪÒõµÀÖÐÈéËá¸Ë¾úº¬Á¿µÄ¼ì²âÔöÌíÁËһ˫“»ÛÑÛ”¡£

\

±í5.¹ýÑõ»¯ÇâŨ¶È¸Ä±äÒõµÀ·ÖÃÚÎïÖ÷ÒªÖ¸±ê¼ì³öÂʱȽÏ[9]

ÈôÒõµÀÄÚ»·¾³ÎÉÂÒ£¬ÇÒ¼ÓµÂÄɾú¡¢ÆÕÀ×ÎÖ¾ú¡¢¶¯Íä¸Ë¾úµÈ΢ÉúÎï´óÁ¿´æÔÚʱ£¬»áµ¼ÖÂBV¡£ÔÚÒõµÀ»·¾³ÖУ¬ÍÙÒºËáÜÕø»îÐÔÓëBVÃÜÇÐÏà¹Ø[10]¡£ÍÙÒºËáÜÕøÊÇÒ»ÖÖøµ°°×£¬Æðµ½Ë®½â×÷Óã¬ÆÕÀ×ÎÖ¾ú¡¢Äâ¸Ë¾ú¼°²¿·Ö¼ÓµÂÄɾú¾ßÓдËøµÄ»îÐÔ£¬¸¬°±Ëá°±»ùëÄø¶Ô¼ÓµÂÄɾúºÍ¶¯Íä¸Ë¾ú¾ßÓÐÏà¹ØÃ¸µÄ»îÐÔ[11]£»¶øÏßË÷ϸ°ûÊÇÕï¶ÏBVµÄÖØÒªÌõ¼þ£¬Òò´Ë¿ÉÒÔÓÃÍÙÒºËáÜÕø¡¢¸¬°±Ëá°±»ùëÄø½áºÏ¾µ¼ìÕï¶ÏBV£¬¼õÉÙ©¼ìÂÊ£¬Ê¹½á¹û¸ü¾«×¼¡£

½ð»ÆÉ«ÆÏÌÑÇò¾ú¡¢·à³¦Çò¾ú¡¢B ×åÁ´Çò¾úºÍ´ó³¦°£Ï£ÊϾúµÈÐèÑõ¾úȺ£¬´óÁ¿´æÔÚÓÚÒõµÀÖÐÔòÈÝÒ×ÒýÆðAV¡£β-ÆÏÌÑÌÇÈ©Ëáø[6]£¬Ò²±»³ÆÎªβ-ÆÏÌÑÌÇÈ©Ëáøˮ½âø£¬ÊÇÒ»ÖÖÌÇÜÕÀàË®½âø£¬ÌØÒìµØ¸»º¬Óڴ󳦸˾úÖУ¬ÒÔËľÛÌåÐÎʽ´æÔÚ£¬β-ÆÏÌÑÌÇÈ©Ëáø¼ø¶¨ÒõµÀ·ÖÃÚÎïÖÐÐèÑõ¾úȺ£¬¾ßÓкܸߵÄÃô¸Ð¶ÈºÍÌØÒìÐÔ£¬¸¨ÖúÌáʾAVÓÐÒ»¶¨µÄÒâÒå¡£

¸¾¿Æ·ÖÃÚÎïÖÐÈô´æÔÚÕæ¾ú¡¢µÎ³æ¿Éµ¼ÖÂVVC¡¢TV¡£80%~90%µÄVVCÊǰ×É«ÄîÖé¾ú£¬ÉÙ²¿·ÖΪ¹â»¬ÄîÖé¾ú¡¢½üƽ»¬ÄîÖé¾ú»òÈÈ´øÄîÖé¾úµÈÒýÆð¡£°×É«ÄîÖé¾ú¾ßÓа±»ùÆÏÌÑÌÇÜÕø[12,13]£¬µÎ³æÒ²Í¬Ñù¾ßÓиÃø[14]£¬µ«°±»ùÆÏÌÑÌÇÜÕøͬʱÑôÐÔÔòÎÞ·¨Åбð³öµÎ³æ»òÕæ¾ú¸ÐȾ¡£Õý³£°×´øµÄpH£º3.8~4.5£¬ÈéËá¸Ë¾úͨ¹ýÒõµÀÁÛ×´ÉÏÆ¤Ï¸°ûËùÌṩµÄÌÇÔ­ÎªÓªÑøÎïÖÊ£¬ÔöÖ³·Ö»¯£»¶øµÎ³æµÄ³öÏÖÄÜÏûºÄ»òÍÌÊÉÒõµÀÉÏÆ¤Ï¸°ûµÄÌÇÔ­£¬×è°­ÈéËáÉú³É£¬Ê¹ÒõµÀpHÔö¸ß£¬²»µÍÓÚ4.8£»µ±ÒõµÀÄÚµÄÌÇÔ­Ôö¶àʱ£¬pH½µµÍ£¬´ËʱÄîÖé¾úÈÝÒ×·±Ö³£¬Òò´ËVVC»¼Õß¶à¼ûÌÇÄò²¡»¼Õß»òÕßÔи¾µÈ¡£×ÛÉÏËùÊö£¬°±»ùÆÏÌÑÌÇÜÕø¿ÉÓëpHÁªºÏ¼ì²â£¬µ±°±»ùÆÏÌÑÌÇÜÕøÑôÐÔʱ£¬pH≥4.8¿ÉÄÜΪTV£¬¶øpH≤4.6Ôò¿ÉÄÜΪVVC¡£

¶àÊýÒõµÀÑ×»¼Õß¾µÏ»á³öÏֺܶà°×ϸ°û£¬ÌرðÊǶàºË°×ϸ°û¡£¶àºË°×ϸ°ûÇ÷»¯×÷Óûáͨ¹ýÒõµÀÉÏÆ¤Ï¸°ûÕ³Ä¤ÉøÍ¸µ½·ÖÃÚÎïÖУ¬°×ϸ°ûõ¥Ã¸ÊÇ´æÔÚÓÚ°×ϸ°û£¨ÖÐÐÔÁ£Ï¸°û£©Ä¤±íÃæÉϵÄÒ»ÖÖµ°°×ÖÊ£¬Òò´Ë°×ϸ°ûµÄÊýÁ¿¶àÉÙÒ²¼ä½Ó·´Ó³Á˰×ϸ°ûõ¥Ã¸µÄº¬Á¿¡£

Ñõ»¯Ã¸ÓÃÓÚ¼ø¶¨ÒõµÀ·ÖÃÚÎïÖÐÌØ¶¨¾úȺ£¬¾ßÓÐÒ»¶¨µÄÃô¸Ð¶ÈºÍÌØÒìÐÔ£¬ÊÇÁܲ¡ÄÎɪ¾ú³õ²½É¸Ñ¡Ö¸±êÖ®Ò»¡£

Ëæ×Åҽѧ¼ì²â¼¼ÊõµÄ²»¶ÏÍêÉÆ£¬Ä¿Ç°ÊµÑéÊÒÏà¼ÌʹÓøɻ¯Ñ§ÓëÓÐÐγɷÖÁªºÏ¼ì²âµÄ·½Ê½£¬¼´¸É»¯Ñ§¸¨ÖúÓÐÐγɷּì²â×ÛºÏÅж¨½á¹û£¬Ìá¸ß½á¹ûµÄ¼ì³öÂÊ¡£¶øÈ«×Ô¶¯ÒÇÆ÷·¨¼ì²â°×´ø³£¹æÓ봫ͳÊÖ¹¤·¨Ïà±È£¬²»½ö¿ÉÒÔ±£Ö¤½á¹û׼ȷ¶È£¬»¹¿ÉÒÔÌáÉý¹¤×÷ЧÂÊ£¬Òò´ËÈ«×Ô¶¯ÒÇÆ÷·¨¼ì²â°×´ø³£¹æÒѳÉΪĿǰʵÑéÊÒ¼ì²âµÄÁ÷ÐÐÇ÷ÊÆ¡£

ÀÖÓãµç¾º¿Æ¼¼¹É·ÝÓÐÏÞ¹«Ë¾£¬È«ÇòµÚÒ»¼Ò³É¹¦ÑÐÖÆ²¢Éú²ú³öÈ«×Ô¶¯¸¾¿Æ·ÖÃÚÎï·ÖÎöϵͳµÄ³§¼Ò£¬¿ª±ÙÁËʵÑéÊÒ°×´ø³£¹æ¼ì²âÓÉÊÖ¹¤·¨ÂõÏò“È˹¤ÖÇÄÜ”µÄмÍÔª¡£¼ì²âÏîÄ¿£º¸É»¯Ñ§9Ï°×ϸ°ûõ¥Ã¸¡¢ÍÙÒºËáÜÕø¡¢β-ÆÏÌÑÌÇÈ©Ëáø¡¢N-ÒÒõ£°±»ù¼ºÌÇÜÕø¡¢¸¬°±Ëá°±»ùëÄø¡¢Ñõ»¯Ã¸¡¢pH¡¢ÈéËá¡¢¹ýÑõ»¯Ç⣩+ÓÐÐγɷÖ8Ï°×ϸ°û¡¢ºìϸ°û¡¢Õæ¾ú£¨æß×Ó¡¢¾úË¿£©¡¢µÎ³æ¡¢¸Ë¾ú¡¢ÔÓ¾ú¡¢ÏßË÷ϸ°û£©+Çå½à¶È£¬¿ÉÌṩ°×´ø³£¹æ¼ì²âµÄ¸÷ÏîÖ¸±ê£¬¸É»¯Ñ§¸¨ÖúÓÐÐγɷÖ£¬ÏòÁÙ´²Ìṩ³£¹æ¼ì²â½á¹û£¬¸¨ÖúÌáʾÁÙ´²Õï¶ÏAV¡¢BV¡¢VVC¡¢TV¼°»ìºÏÐÔÒõµÀÑ׵ȳ£¼û¸¾¿Æ¼²²¡¡£

\

¡¾²Î¿¼ÎÄÏס¿

[1] GHDx. GBD results tool[EB/OL]. [2018-02-05]. http://ghdx.healthdata.org/gbd-results-tool. [2] ÁÎÇØÆ½£¬³ÂÈñ.´óÊý¾ÝÔÚ¸¾²ú¿ÆÎ¢Éú̬ÁìÓòÖеÄÓ¦ÓÃÏÖ×´¼°Õ¹Íû.ÖйúʵÓø¾¿ÆÓë²ú¿ÆÔÓÖ¾2018Äê1 ÔµÚ34¾íµÚ1ÆÚ. [3] ÑîÆ¼.¸¾¿Æ¼²²¡µÄÖÖÀ༰¶ÔÅ®ÐÔµÄΣº¦.Öйú±£½¡ÓªÑø. 2013.01£¨ÉÏ£© [4] ÌïȪ£¬Ñ¦ÑÞ£¬ÀîÄÈ£¬µÈ.4019Àý¸¾¿ÆÃÅÕﲻ֢ͬ״»¼ÕßÒõµÀ΢Éú̬״¿ö·ÖÎö£ÛJ£Ý.Öйú΢Éú̬ѧÔÓÖ¾£¬ 2013£¬25£¨12£©£º1432-1435 [5] ÁÎÇØÆ½.Å®ÐÔÒõµÀ΢Éú̬ͼÆ×.ÈËÃñÎÀÉú³ö°æÉç.2014.04.µÚÒ»°æ [6] Kovachev SM.Obstetirc and eynecological diseases and complications Resultingfromvaginal dysbacteriosis[J].MicrobEcol,2014,68(2):173-184(3):237-239 [7] ¿µ°×,Ô¬½ÜÀû.ÈéËá¾úµÄ΢Éú̬ѧÑо¿½øÕ¹[J].Öйú΢Éú̬ѧÔÓÖ¾.2005,17 [8] ÂÀ»ÛÏÍ.ÒõµÀÇå½à¶È·Ö¼¶ÓëÒõµÀÉú̬»·¾³µÄÏà¹ØÐÔ.ÖйúʵÓÃÒ½Ò©.2015Äê7ÔµÚ10¾íµÚ19ÆÚ [9] ³ÂµÂÁé.ÒõµÀ·ÖÃÚÎï΢Éú̬¼ì²âÖ¸±êµÄÁÙ´²Ó¦ÓÃ.Öйú΢Éú̬ѧÔÓÖ¾.2007Äê4ÔµÚ19¾íµÚ2ÆÚ [10]BradshawCS,MortonAN,GarlandSM,etal.Evaluation of a Point-of-CareTest,BV Blue,and Clinical and Laboratory Criteria for Diagnosis of Bacterial Vaginosis[J].JClin Microbiol,2005,43(3):1304-1308 [11] ÍõÔóÓî.ÒõµÀÑ×ÎåÁª¼ìÔÚ°×´ø³£¹æ¼ì²âÖеÄÓ¦ÓÃÑо¿.ÖйúƤ·ôÐÔ²¡Ñ§ÔÓÖ¾.2010.1.µÚ24¾íµÚ1ÆÚ. [12]CannonRD, NiimiK, JenkinsonHF, etal.Molecularcloning and expression of the Candida albicans β-N-acetyl glucos aminidase (HEX1)gene[J] .JBacteriol, 1994,176(9):2640 -2647.[9] [13]HorschM,MayerC,SennhauserU,etal.β-N-acetyl hexosaminidase:atarget for the design of antifungalagents[J] .Pharmacol Ther, 1997,76(1-3) :187-218. [14]SanonA, Tournaire-ArellanoC,ElHageSY,etal.N-acetyl-beta-D-hexossaminidase from Trichomonas vaginalis:substrate specificity and activity of in hibitors[J] .Biomed Pharmacother, 2005,59(9):245-248

 

¹ºÂòÇþµÀ
ÒµÎñ×Éѯ
¹Ù·½Î¢ÐÅ
È˲ÅÒý½ø
ÏÂÔØÖ§³Ö

ÊÛºó·þÎñÈÈÏß

4008116695 / 4008116605£¨¹úÄÚ£©

4008087597£¨¹ú¼Ê£©

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿